U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314528) titled 'Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer' on Aug. 28, 2025.
Brief Summary: The goal of this clinical trial is to see if adding a weight loss medication (GLP-1 receptor drug) to patients with an increased BMI receiving treatment for rectal cancer prior to surgery (total neoadjuvant chemoradiotherapy) improves cancer outcomes. The main questions it aims to answer is
1. Does the drug increase weight loss in rectal cancer patients with a high BMI
2. Does the drug improve response rates to chemotherapy and radiotherapy
3. Does the drug improve survival outcomes and if cancer retur...